NewsRoom Articles - Page 123 of 221

ThursdayApr 14, 2022 3:46 pm

Study Finds Malnutrition Linked to Decline in Kidney Function in Older Individuals

A new study has found that malnutrition is associated with chronic kidney disease, increased risk of kidney function decline and poor kidney function in older adults who don’t suffer from advanced kidney disease. Chronic kidney disease, which is sometimes referred to as chronic kidney failure, occurs when an individual’s kidneys gradually lose function and fail to filter blood as they should. Treatment for this disease is focused on slowing the progression of damage to the kidneys, which isn’t easy to do if the disease has already advanced to end-stage kidney failure. The study was conducted by researchers at the Cheeloo…

WednesdayApr 13, 2022 1:38 pm

Research Emphasizes Importance of Screening for Unhealthy Consumption of Alcohol

New research has found that during primary care visits, screening for unhealthy consumption of alcohol by patients through the use of a validated questionnaire is rarely done. This is despite the current recommendations provided by the U.S. Preventive Services Task Force. Figures show that between 2014 and 2016, screening was performed during only about 3% of office visits. Brittany Charrerton, a research fellow in the Department of Internal Medicine, stated that primary care physicians were usually overwhelmed with many patient health concerns and sometimes performing screening for alcohol consumption of patients was forgotten. Data from the National Institute on Alcohol…

WednesdayApr 13, 2022 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”) CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there The study…

TuesdayApr 12, 2022 1:28 pm

University of Virginia Cancer Center Helps Update National Brain Cancer Treatment Guidelines

Around 700,000 Americans are estimated to live with brain cancer, and by the end of 2022, nearly 90,000 more will have been diagnosed with the deadly disease. In 2020, brain and Central Nervous System (CNS) tumors took more than 200,000 lives worldwide. It is a debilitating condition that can significantly reduce a patient and their family’s quality of life. The most common treatment methods for brain cancer are surgery, chemotherapy and radiation. While these treatment options can allow people with brain tumors to live for years after they are diagnosed, they aren’t risk free. Chemotherapy and radiation, for instance, cause…

TuesdayApr 12, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa) The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion…

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

MondayApr 11, 2022 2:29 pm

Study Links Excessive Napping to Increased Risk of Developing Alzheimer’s

New research has found that excessive napping in the daytime for older individuals may indicate a heightened risk of Alzheimer’s disease. The study, which involved a cohort of older individuals, was carried out by researchers at Brigham and Women’s Hospital. The researchers discovered a link between cognitive aging and excessive napping in the daytime, noting that being diagnosed with Alzheimer’s accelerated the increase in daytime napping as an individual aged while excessive napping during the daytime forecasted an elevated future risk of Alzheimer’s. The study’s findings were reported in “Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association.” Peng Li,…

MondayApr 11, 2022 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo…

MondayApr 11, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier The blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumors By crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central nervous system cancers annually This year, about 25,050 adults (14,170 men and 10,880 women) will be diagnosed with malignant central nervous system (“CNS”) tumors – cancerous tumors that start in the spinal…

FridayApr 08, 2022 2:46 pm

Gun Violence Survivors at Higher Risk of Being Diagnosed with Mental Health Issues

Estimates show that in the United States approximately 85,000 individuals survive gun injuries, while another 40,000 are killed by guns annually. New research has found that the consequences of gun violence extend far beyond the damage caused by the injury. Long-term repercussions include substance-use disorders, worsened mental health and increase in healthcare costs incurred for survivors as well as increased mental health conditions for their significant others and children. The study was carried out by researchers at Harvard Medical School. Its findings were reported in the “Annals of Internal Medicine.” This is the first quasiexperimental, large-scale study to look into…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Study Finds Malnutrition Linked to Decline in Kidney Function in Older Individuals

Research Emphasizes Importance of Screening for Unhealthy Consumption of Alcohol

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

University of Virginia Cancer Center Helps Update National Brain Cancer Treatment Guidelines

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

Study Links Excessive Napping to Increased Risk of Developing Alzheimer’s

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

Gun Violence Survivors at Higher Risk of Being Diagnosed with Mental Health Issues

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search